Revenue and Profit - Revenue for Q3 2024 was CNY 121,926,877.95, an increase of 4.79% year-over-year[2] - Net profit attributable to shareholders decreased by 25.04% to CNY 20,383,291.92 in Q3 2024[2] - The net profit attributable to shareholders for the year-to-date period decreased by 138.05% to CNY -14,124,681.40[6] - Total operating revenue for the first three quarters of 2024 reached ¥248,302,819.25, an increase from ¥239,426,012.53 in the same period of 2023, representing a growth of approximately 3.65%[15] - The net profit for the first three quarters of 2024 was a loss of ¥17,020,443.48, compared to a profit of ¥36,484,405.67 in the same period of 2023[16] - The operating profit for the first three quarters of 2024 was a loss of ¥18,962,951.36, down from a profit of ¥43,195,061.03 in 2023[16] Research and Development - R&D investment totaled CNY 16,167,081.47, representing 13.26% of revenue, an increase of 1.29 percentage points year-over-year[3] - Research and development expenses increased to ¥37,754,809.62 from ¥30,259,274.15, reflecting a growth of approximately 24.8%[15] - The company is advancing its mRNA product development and production line construction, with progress in new vaccine projects such as virus-like particle vaccines[8] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,582,011,409.68, a decrease of 0.75% from the previous year[3] - The company's total assets amount to 1,582,011,409.68 RMB, a slight decrease from 1,593,994,285.77 RMB in the previous period[12] - Total liabilities increased to ¥106,336,418.34 from ¥86,926,310.95, indicating a growth of approximately 22.2%[15] - Total equity decreased to ¥1,475,674,991.34 from ¥1,507,067,974.82, a decline of about 2.09%[15] Cash Flow - The company reported a net cash flow from operating activities of CNY 12,473,617.62 year-to-date[2] - The net cash flow from operating activities for the first three quarters of 2024 was 12,473,617.62, a significant improvement from -54,675,362.33 in the same period of 2023[19] - Cash inflow from investment activities totaled 811,780,345.26, down from 1,149,584,784.08 in the previous year[19] - The net cash flow from investment activities was 55,671,682.19, compared to 74,107,977.58 in the prior year[19] - The net increase in cash and cash equivalents at the end of the period was 98,046,790.72, up from 38,876,146.49 in the previous year[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 9,288[9] - The largest shareholder, Yang Yufang, holds 90,063,197 shares, representing 21.93% of the total shares[10] - The company has a total of 43,199,898 shares held by the foreign entity UNITED BIOMEDICAL, INC., accounting for 10.52% of the total shares[10] Operating Costs and Expenses - Total operating costs increased to ¥259,262,501.74 from ¥198,576,174.34, marking a rise of about 30.54%[15] - The company reported a significant increase in sales expenses, which rose to ¥77,225,498.63 from ¥60,578,131.36, an increase of approximately 27.5%[15] - Cash outflow for dividend distribution and interest payments was 14,338,485.84, down from 32,773,668.59 in 2023[19]

证券代码：688098 证券简称：申联生物 公告编号：2024-024 监事会审核了公司《2024 年第三季度报告》，了解并监督了公司报告的编 制、审核过程，监事列席董事会并了解董事会对第三季度报告的审议情况，监事 会认为公司《2024 年第三季度报告》的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏，2024 年第三季度报告的编制、审核以及董事会的审 议程序符合法律法规、《公司章程》等相关规定。 投票结果：3 票同意，0 票反对，0 票弃权。 具体内容详见公司同日在上海证券交易所网站(www.sse.com.cn)披露的《申 联生物医药（上海）股份有限公司 2024 年第三季度报告》。 （二）审议通过《关于使用部分闲置募集资金进行现金管理的议案》 申联生物医药（上海）股份有限公司 第三届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 申联生物医药（上海）股份有限公司（以下简称"公司"）第三届监事会第 十一次会议于 2024 年 10 月 30 日在公司综合 ...

Group 1: Company Overview and Technology Development - The company has established a mature mRNA technology platform, referred to as mRNA 2.0, which includes proprietary circular RNA technology and a full-process R&D capability from antigen design to commercial production [2]. - The mRNA technology platform is being developed for both human and veterinary applications, with significant potential in preventing animal infectious diseases [1][2]. - The company is constructing a GMP production facility for mRNA vaccines and drugs in Shanghai, which will enable comprehensive solutions from early research to commercial production [2]. Group 2: Product Pipeline and Market Strategy - The company is advancing several mRNA vaccines, including those for rabies, swine fever, and African swine fever, with plans to launch the swine fever vaccine in 2025 after obtaining regulatory approval [2][3]. - The company employs a differentiated R&D strategy to avoid product homogeneity and focuses on mainstream products with strong market competitiveness [3]. - The sales model includes government procurement, large customer sales, and distribution channels, with government procurement being the largest segment [3]. Group 3: Financial Performance and Future Outlook - The company aims to enhance operational efficiency and reduce costs to improve financial performance in 2024, balancing short-term and long-term goals [4]. - The marketing strategy involves understanding customer needs, developing new products, and optimizing market strategies to increase sales of key vaccines [4]. - The company is exploring strategic partnerships with downstream enterprises to enhance market position and performance [4].

关于召开 2024 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：688098 证券简称：申联生物 公告编号：2024-023 重要内容提示： 申联生物医药（上海）股份有限公司 投资者可于 2024 年 10 月 14 日(星期一) 至 10 月 18 日(星期五)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 slsw@slbio.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 申联生物医药（上海）股份有限公司（以下简称"公司"）已于 2024 年 8 月 30 日发布公司 2024 年半年报告，为便于广大投资者更全面深入地了解公司 2 024 年半年经营成果、财务状况，公司计划于 2024 年 10 月 21 日下午 15:00-16: 00 举行 2024 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2024 年半年度的经营 成果及财务指标的具体情况与投资者 ...

证券代码：688098 证券简称：申联生物 公告编号：2024-022 申联生物医药（上海）股份有限公司 关于董事会、监事会延期换届选举的提示性公告 特此公告。 申联生物医药（上海）股份有限公司董事会 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 申联生物医药（上海）股份有限公司（以下简称"公司"）第三届董事 会、第三届监事会将于 2024 年 9 月 26 日任期届满。鉴于公司新一届董事会、 监事会换届工作尚在积极筹备中，为确保公司董事会、监事会相关工作的稳定 性和连续性，公司董事会、监事会换届选举工作将延期举行，公司董事会各专 门委员会及高级管理人员的任期亦相应顺延。 在新一届董事会、监事会换届选举工作完成之前，公司第三届董事会、第 三届监事会、董事会各专门委员会及公司高级管理人员将依照相关法律法规和 《申联生物医药（上海）股份有限公司章程》等相关规定继续履行相应的职责 和义务。 公司董事会、监事会延期换届选举不会影响公司的正常运营。公司将积极 推进董事会、监事会的换届选举工作，尽快完成董事会与监事会的换届选举工 作，并及 ...

一、新技术赋能创新产品，多元化战略持续拓展 申联生物医药（上海）股份有限公司 关于2024年度"提质增效重回报"行动方案的 半年度评估报告 为响应新"国九条"政策，落实以"投资者为本"的理念，推动上市公司 持续优化经营、规范治理和积极回报投资者，申联生物医药（上海）股份有限 公司（以下简称"公司"）结合公司发展战略、经营情况及财务状况，基于对 公司未来发展前景的信心及价值的认可，公司于2024年4月27日发布了《2024年 度"提质增效重回报"行动方案》（以下简称"行动方案"），为公司2024年 度提质增效重回报行动制定出明确的工作方向。公司根据行动方案内容，积极 开展和落实各项工作，现将2024年上半年的主要工作成果报告如下。 行及监督机制，明确合同管理职责，防控经营风险，提高公司经营效益。 公司督促董事会成员及高级管理人员恪守职责，加强董监高对证券市场法 律法规的培训和学习，积极落实《公司法》修订、独立董事制度改革等相关意 见，有序开展各项制度的修订和持续宣贯。公司积极组织公司董事、监事、高 级管理人员参加证券市场法律法规及专业知识培训，2024年上半年完成培训13 次。积极传递新"国九条""科八条"等资 ...

Financial Performance - The company's operating revenue for the first half of 2024 was ¥126,375,941.30, representing a year-on-year increase of 2.68% compared to ¥123,071,527.99 in the same period last year[12]. - The net profit attributable to shareholders of the listed company was -¥34,507,973.32, a significant decline of 447.44% from a profit of ¥9,932,169.99 in the previous year[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥35,444,045.99, marking a drastic decrease of 1059.88% compared to ¥3,692,537.44 in the same period last year[12]. - The net cash flow from operating activities for the reporting period was -805,633.37 RMB, a significant decrease compared to -43,825,814.79 RMB from the previous year[13]. - The net assets attributable to shareholders decreased by 3.28% to 1,439,851,706.03 RMB from 1,488,732,219.35 RMB at the end of the previous year[13]. - The total assets decreased by 2.31% to 1,557,172,922.80 RMB from 1,593,994,285.77 RMB at the end of the previous year[13]. - Basic earnings per share were -0.08 RMB, a decline of 500.00% compared to 0.02 RMB in the same period last year[13]. - The company achieved a total revenue of 30,508.14 million RMB, with a net profit of 12,654.61 million RMB for the first half of 2024[54]. - The company reported a net loss of ¥36,435,616.03 for the first half of 2024, a decline from a net profit of ¥9,932,169.99 in the same period of 2023[160]. - The total comprehensive income attributable to the parent company was -¥34,507,973.32, compared to ¥9,932,169.99 in the previous year, indicating a significant decline[161]. Research and Development - The R&D investment accounted for 37.00% of operating revenue, an increase of 3.69 percentage points from 33.31% in the previous year[13]. - The company is actively tracking animal disease trends to develop cutting-edge products and technologies, enhancing collaboration between R&D and marketing[14]. - The company has developed a new bivalent synthetic peptide vaccine for foot-and-mouth disease, which is highly safe, efficient, and stable, with a long-lasting immune response[22]. - The company is investing in mRNA technology and other advanced biopharmaceutical techniques, which are expected to drive future vaccine development[41]. - Total R&D investment increased by 14.08% year-on-year, reaching approximately ¥46.76 million, with R&D expenses accounting for 37.00% of operating revenue, up from 33.31%[50]. - The company has filed for a total of 138 patents, with 85 patents granted, reflecting a strong commitment to innovation and development[49]. - The company has established five major platforms for inactivated vaccines, including dual-strain reverse genetics technology and dual high-efficiency suspension culture technology, which have led to significant advancements in vaccine production[44]. - The mRNA vaccine technology platform has made significant progress, with core technologies established for mRNA design and production, enabling the development of vaccines for major animal diseases such as African swine fever[46]. - The company has made significant advancements in synthetic peptide vaccine technology, with multiple industry-leading core technologies established[45]. Market and Industry Trends - The veterinary biological products industry in China achieved a production value of 17.736 billion CNY and sales of 16.567 billion CNY in 2022, with a gross profit of 9.141 billion CNY, resulting in an average gross margin of 55.18%[30]. - The market size for pig biological products reached 7.642 billion CNY, accounting for 46.13% of the total market, while poultry biological products accounted for 40.12% with a market size of 6.647 billion CNY[31]. - The industry is facing challenges such as low concentration, structural overcapacity, and intensified competition, prompting a new phase of development and consolidation[30]. - The Chinese veterinary biological products industry is increasingly focusing on international market participation and collaboration, particularly in response to global animal disease prevention efforts[30]. - The average profit margin for the pig biological products sector is reported at 12.91%[31]. Product Development and Innovation - The company has developed a range of vaccines including inactivated vaccines for foot-and-mouth disease and synthetic peptide vaccines, with ongoing construction of additional production lines for live and inactivated vaccines[40]. - The company has successfully launched a bivalent inactivated vaccine for swine foot-and-mouth disease, which has received high recognition for its effectiveness and safety from customers[44]. - The company is enhancing its core technology platforms to provide safe and effective disease prevention and diagnostic solutions, with a focus on protein engineering and antibody technology[40]. - The company is focusing on the development of new adjuvants to enhance immune responses for new vaccines, including immune-modulating and antigen-delivery adjuvants[42]. - The company has introduced a bivalent inactivated vaccine for cattle and sheep foot-and-mouth disease, which features strong immunogenicity and cross-protection capabilities[66]. Financial Management and Investments - The company plans to invest 129.03 million yuan in the animal inactivated vaccine project, utilizing 99.03 million yuan of raised funds[92]. - The company has approved the use of up to CNY 5,000 million of idle raised funds for cash management, with a maximum balance of CNY 0 at the end of the reporting period[146]. - The total amount of raised funds is CNY 44,000 million, with a net amount after issuance costs of CNY 40,017.50 million[142]. - The company has not disclosed any new major contracts or significant changes in the use of raised funds during the reporting period[145]. - The company plans to increase R&D investment, with multiple new veterinary drug projects currently underway, aiming to enhance core competitiveness[79]. Environmental Responsibility - The company invested 994,300 CNY in environmental protection during the reporting period[104]. - The company has implemented carbon reduction measures, optimizing energy-saving facilities and enhancing energy consumption management, resulting in effective cost savings and environmental protection[120]. - The company has passed a clean production audit in December 2022, demonstrating its commitment to environmental responsibility[119]. - The company has developed emergency response plans for environmental incidents, complying with national regulations[116]. - The company has received pollution discharge permits from the environmental authorities in Shanghai and Lanzhou, valid since November 2022 and April 2022 respectively[118]. Corporate Governance and Compliance - The company has a structured plan to address any unfulfilled commitments, ensuring accountability and future compliance[124]. - The company will ensure that any related party transactions are conducted in compliance with relevant laws and regulations, protecting the interests of shareholders[130]. - The company has implemented strategies to ensure compliance and transparency, with no significant omissions or misleading statements reported[129]. - The company is committed to optimizing its innovation and R&D pillars to ensure timely conversion of research results into practical outputs, driving sustainable development[70]. - The company has not received any penalties or corrective actions for suspected violations during the reporting period[139]. Strategic Outlook - The company provided an optimistic outlook, projecting a revenue growth of 25% for the second half of 2024, driven by new product launches[127]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2025[129]. - A strategic acquisition was announced, with the company acquiring a competitor for 500 million, aimed at enhancing its product portfolio[125]. - The company is actively expanding its international business, particularly in the "Belt and Road" markets, focusing on product exports and overseas technology investments[77]. - The company is focusing on quality management, with its quality management system continuously improving to meet GMP and ISO9001 standards, expanding its testing capabilities to include various animal species[76].

证券代码：688098 证券简称：申联生物 公告编号：2024-019 （二）协议主体的基本情况 申联生物医药（上海）股份有限公司 关于对外投资暨签署《战略合作协议》的自愿性披 露公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 近日，申联生物医药（上海）股份有限公司（以下简称"公司"）与上 海建毅腾创生物医药科技有限公司（以下简称"腾创生物"）签署了《战略合 作协议》及《投资协议》。基于公司在生物大分子治疗、预防及诊断的研发、 生产等方面拥有深厚的研发技术实力和完备的生产能力，腾创生物在宠物药品 临床需求、药物靶点分析和筛选等方面具备一定的优势，为了充分利用双方各 自资源和优势，双方将在宠物治疗类、预防类、诊断类生物制品等领域全面开 展深入合作，实现战略共赢。同时，公司将以现金出资投资参股腾创生物，成 为腾创生物的重要参股股东。本事项无需提交公司董事会及股东大会审议。 一、《战略合作协议》的主要内容 （一）协议主体 甲方：申联生物医药（上海）股份有限公司 乙方：上海建毅腾创生物医药科技有限公司 | 公司 ...

北京达辉（上海）律师事务所 关于 申联生物医药（上海）股份有限公司 2023 年年度股东大会 之 法 律 意 见 书 关于申联生物医药（上海）股份有限公司 2023 年年度股东大会 之 法律意见书 文号：达辉京证字[2024]第 S170005F001 号 致：申联生物医药（上海）股份有限公司 北京达辉（上海）律师事务所 中国·上海市 南京西路 1515 号·静安嘉里中心 13 楼 北京达辉（上海）律师事务所 北京达辉（上海）律师事务所(以下称"本所")是具有中华人民共和国法律执业资格 的律师事务所。根据法律顾问协议，本所指派律师出席申联生物医药（上海）股份有 限公司（以下称"申联生物"或"公司"）2023 年年度股东大会(以下称"本次股东 大会")，并对公司提供的与题述事宜有关的法律文件及其他文件、资料予以了核查、 验证。现依据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东 大会规则》及其他中国1相关法律、法规、规章及规范性文件（以下合称"法律法 规"）以及《申联生物医药（上海）股份有限公司章程》（以下称"《公司章 程》"）的规定，就本次股东大会相关事项出具本法律意见书。 公司在使用本法律意 ...

证券代码：688098 证券简称：申联生物 公告编号：2024-017 申联生物医药（上海）股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2024 年 05 月 17 日 （二） 股东大会召开的地点：上海市闵行区江川东路 48 号公司综合楼一楼会议 室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 15 | | --- | --- | | 普通股股东人数 | 15 | | 2、出席会议的股东所持有的表决权数量 | 244,183,733 | | 普通股股东所持有表决权数量 | 244,183,733 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的 | 59.4636 | | 比例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例 | 59.4636 | | ...